Related Experiment Videos
DPI 201-106 for severe congestive heart failure
J B Kostis1, C R Lacy, J J Raia
1Division of Cardiovascular Diseases and Hypertension, UMDNJ-Robert Wood Johnson Medical School, New Brunswick 08903-0019.
The American Journal of Cardiology
|December 1, 1987
Summary
DPI 201-106, a novel oral inotropic agent, improved hemodynamics in severe congestive heart failure patients. This drug enhanced cardiac function by increasing myofilament calcium sensitivity and sodium current.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Severe congestive heart failure (CHF) presents significant hemodynamic challenges.
- Novel therapeutic agents with improved efficacy and safety profiles are needed for CHF management.
Purpose of the Study:
- To evaluate the safety and efficacy of DPI 201-106, a novel oral inotropic agent, in patients with severe CHF.
- To assess the dose-dependent hemodynamic effects of DPI 201-106.
Main Methods:
- A double-blind, randomized, placebo-controlled study.
- 15 patients with severe CHF received single oral doses of DPI 201-106 (80 and 100 mg).
- Hemodynamic parameters, including cardiac index and QTc interval, were monitored.
Main Results:
- Dose-dependent increases in cardiac index (25%), left ventricular stroke work index (24%), and left ventricular stroke volume index (32%) were observed.
- A significant increase in QTc interval (7%) was noted, correlating with drug plasma levels and ventricular ectopy.
- No significant changes in heart rate or systemic arterial pressure were detected.
Conclusions:
- DPI 201-106 demonstrated positive hemodynamic effects in patients with severe CHF.
- The drug's novel mechanism, enhancing myofilament calcium sensitivity and prolonging sodium current, contributes to its inotropic action.
- Further research is warranted to fully elucidate the safety and efficacy profile of DPI 201-106 in CHF treatment.